Cover Image
市場調查報告書

生物相似藥胰島素的市場進入

Biosimilar Insulin Market Access

出版商 Datamonitor Healthcare 商品編碼 498961
出版日期 內容資訊 英文 19 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物相似藥胰島素的市場進入 Biosimilar Insulin Market Access
出版日期: 2018年01月26日 內容資訊: 英文 19 Pages
簡介

本報告提供生物相似藥胰島素的市場進入趨勢調查,美國及歐盟5國的首發品的兼容性相關規定,與首發品的兼容性及生物相似藥的醫療費削減相關的醫生、保險者的各種見解,生物相似藥的引進推動中可使用的市場進入工具,現有藥物的處方集刊載、契約維持的策略等彙整資料。

摘要整理

美國

  • 考察、策略性建議
  • 美國的保險者:對生物相似藥藥Basaglar引進靜觀性方法
  • 文獻

歐盟5國

  • 考察、策略性建議
  • 因為歐洲藥品管理局 (EMA) 沒有規定兼容性,生物相似藥胰島素的引進依國家而不相同
  • 醫生、保險者:關於生物相似藥胰島素的兼容性有各種見解,不過都同意是降低成本的大機會
  • 保險者:利用生物相似藥給首發品價格壓力
  • 藥局:繼續採購後發品、首發品,不過,觀察到動態定價環境
  • 患者切換需要至少30%的大幅折扣
  • 若有吸引力的折扣,保險者可使用推動Basaglar的引進的各種市場進入工具
  • 文獻

調查手法

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0170584

Overview

Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba. More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • US
  • Insights and strategic recommendations
  • US payers are adopting a wait-and-see approach for biosimilar Basaglar
  • Bibliography

FIVE MAJOR EU MARKETS

  • Insights and strategic recommendations
  • Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
  • Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to reduce costs
  • Payers use biosimilars to pressure originators on pricing
  • Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
  • Patient switching requires significant discounts of at least 30%
  • Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
  • Bibliography

METHODOLOGY

  • Primary research

LIST OF TABLES

  • Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Back to Top